Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Skrit37on May 28, 2021 3:40pm
90 Views
Post# 33288012

RE:RE:RE:RE:RE:From the management circular

RE:RE:RE:RE:RE:From the management circular
LithLover wrote: The 8:1 was planned for the Nasdaq but I think they got talked into by the institutional investors and analysts looking to move the share price over $1 to encourage buying.  

As it turned out we still don't have the exposure to the US market as Jack Lifton just mentioned in the interview with Tripp.

Had they moved to a US exchange first , increased marketing and partnered with the investors/analysts and than the 8:1 r/s might be a differnt story but thats in the past.

They need to:

1) Increase Marketing.
2) list on a OTC US exchange and gain more exposure to help move the SP to $2 or more
3) Once over $2 do the r/s and move to Nasdaq 



 
Mermer2328 wrote:
Its all fine and dandy and I really hope that in the next yr the 2 for 1 splitt will have the SP high enough to trade on the Nazdaq. But this was the same story for doing an 8 to 1 reverse split. so that went from 9 cents to 72.. Where are we now??? All talk. no action. that's what needs to change






As far as uplisting goes.....cut and paste....same reason...only difference is the page # 

June 16 2020 ( from MANAGEMENT INFORMATION CIRCULAR ) sedar

(page 14) Background to and Reasons for the Share Consolidation

"Preparation for potential US listing: the Corporation is looking to prepare for a possible future listing on NASDAQ or other senior US stock exchange. The higher anticipated price of the post-consolidation common shares may help make the Corporation eligible for such a listing."

May 28 2021  ( from MANAGEMENT INFORMATION CIRCULAR ) sedar

(page 15) Background to and Reasons for the Share Consolidation


"Preparation for potential US listing: the Corporation is looking to prepare for a possible future listing on NASDAQ or other senior US stock exchange. The higher anticipated price of the post-consolidation common shares may help make the Corporation eligible for such a listing"




<< Previous
Bullboard Posts
Next >>